Plasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemia.
暂无分享,去创建一个
[1] K. Kuliczkowski,et al. Bone marrow angiogenesis and proliferation in B-cell chronic lymphocytic leukemia. , 2004, Analytical and quantitative cytology and histology.
[2] D. Ribatti,et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. , 2002, Blood.
[3] N. Kay,et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules , 2002, Leukemia.
[4] O. Bairey,et al. Bcl‐2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia , 2001, British journal of haematology.
[5] E. Estey,et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. , 2000, Blood.
[6] S. Molica,et al. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B‐cell chronic lymphocytic leukaemia , 1999, British journal of haematology.
[7] A. König,et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis , 1997, Leukemia.
[8] E. Calleja,et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. , 1996, Blood.
[9] E. Montserrat,et al. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. , 2005, Haematologica.